In this episode of the CFI Podcast, we take a deep dive into the world of drug development—specifically “undruggable drugs”: a category of protein, protein family or even piece of RNA that’s so difficult to target that many researchers don’t even want to touch it.
Jay Bradner, President of the Novartis Institute for BioMedical Research, shares with CFI General Partners Jorge Conde, Vijay Pande, and CFI ’s Hanne Tidnam all the new tools, technologies and breakthroughs which are causing the science of therapeutics to explode in some of these areas where it’s been incredibly difficult (even impossible) in the past. From molecular glues to cell and gene therapies, Bradner shares the behind-the-scenes science stories of what it really takes to make a new drug that shatters the category of an “undruggable” target.
Editor’s Note: This podcast was recorded at the 2020 JP Morgan Healthcare Conference.
Jay Bradner
Jorge Conde is a general partner on the Bio + Health team at Andreessen Horowitz, focused on therapeutics, diagnostics, life sciences tools, and software.
Vijay Pande is the founding general partner of the Bio + Health team at Andreessen Horowitz, focused on the cross-section of biology and computer science.
Hanne Winarsky is the Head of Writer Acquisition & Development at Substack.
The CFI Podcast discusses the most important ideas within technology with the people building it. Each episode aims to put listeners ahead of the curve, covering topics like AI, energy, genomics, space, and more.